Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Conmed (CNMD) EBITDA (2016 - 2025)

Conmed (CNMD) has disclosed EBITDA for 11 consecutive years, with $135.5 million as the latest value for Q4 2020.

  • For the quarter ending Q4 2020, EBITDA fell 4.55% year-over-year to $135.5 million, compared with a TTM value of $460.3 million through Dec 2020, down 12.28%, and an annual FY2025 reading of $59.6 million, down 51.82% over the prior year.
  • EBITDA was $135.5 million for Q4 2020 at Conmed, up from $133.7 million in the prior quarter.
  • Across five years, EBITDA topped out at $142.0 million in Q4 2019 and bottomed at $71.9 million in Q2 2020.
  • Average EBITDA over 5 years is $114.7 million, with a median of $113.4 million recorded in 2018.
  • The sharpest move saw EBITDA increased 17.61% in 2019, then crashed 45.17% in 2020.
  • Year by year, EBITDA stood at $107.0 million in 2016, then increased by 15.89% to $124.0 million in 2017, then rose by 7.02% to $132.7 million in 2018, then increased by 7.03% to $142.0 million in 2019, then decreased by 4.55% to $135.5 million in 2020.
  • Business Quant data shows EBITDA for CNMD at $135.5 million in Q4 2020, $133.7 million in Q3 2020, and $71.9 million in Q2 2020.